JNJJ&J EVP Jennifer Taubert to Retire in Sept 2026
Johnson & Johnson EVP Jennifer Taubert to retire Sept 2026. What investors should know about leadership, strategy and near‑term priorities for JNJ.
JOHNSON & JOHNSON
JNJJNJ Completes Firefly Bio Deal; Partners with Sail
Johnson & Johnson (JNJ) finalizes acquisition of Firefly Bio and announces partnership with Sail Biomedicines, reinforcing its Innovative Medicine strategy.
JOHNSON & JOHNSON
JNJJ&J Lowers 2026 EPS Midpoint After Firefly Deal
Johnson & Johnson (JNJ) cuts 2026 EPS midpoint by $0.64 following the Firefly Bio acquisition. Investor analysis, risks, and historical context.
JOHNSON & JOHNSON
JNJJNJ Board & DePuy Synthes Leadership Update
Johnson & Johnson (JNJ) appoints John Morikis to the board; Namal Nawana named president of DePuy Synthes. Key investor implications on 2025-10-14.
JOHNSON & JOHNSON
JNJJ&J Reports FDA Approvals, AI Launch — JNJ News
J&J (JNJ) wins FDA approvals and launches an AI system on 2025-10-14, advancing oncology and cardiovascular care. Q3 2025 sales $22,471M; watch regulatory/IP risks.
JOHNSON & JOHNSON
JNJJ&J Restructures MedTech Operations
Johnson & Johnson (JNJ) begins MedTech restructuring, exiting certain markets and optimizing sites. Investor-focused analysis on financial and strategic implications.
JOHNSON & JOHNSON
JNJJNJ: Namal Nawana Named President of DePuy Synthes
Johnson & Johnson appoints Namal Nawana to lead DePuy Synthes amid its planned Orthopaedics Business separation. (Oct 14, 2025)
JOHNSON & JOHNSON
JNJJohnson & Johnson Q3 2025: Revenue up 6.8%
JNJ Q3 2025: Revenue up 6.8% to $22,471M; Q3 net earnings $5,152M (nearly double). Company raises sales guidance, cites strength in Innovative Medicine and MedTech.
JOHNSON & JOHNSON
JNJJ&J to Spin Off DePuy Synthes
Johnson & Johnson (JNJ) plans to separate its Orthopaedics unit as DePuy Synthes. Key investor considerations: MedTech strategy, financials, and execution risks.
JOHNSON & JOHNSON